Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC Patients - a Phase II Translational and Biomarker Study Investigating PDL1 Positive and Negative Patients

NCT04392505 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT04392505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04392505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC Patients - a Phase II Translational and Biomarker Study Investigating PDL1 Positive and Negative Patients
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 11, 2020
Completion date
May 1, 2033
Enrollment
100 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, non small cell lung cancer, non small cell lung cancer stage iii, nsclc, nsclc, stage iii